Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Acetate

Generic Name: Acetate

Drug Type: Small Molecule

Chemical Formula: C_₂H_₃O_₂

CAS Number: 71-50-1

Unique Ingredient Identifier: 569DQM74SC

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Vitamin E on Staple Line and Anastomoses of Roux-en-Y Gastric Bypass

Phase 3

Completed

Posted: 2018/12/05

Sponsor:

Hospital General Uni...

ID:NCT03765827

Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Phase 3

Completed

Posted: 2018/11/23

Sponsor:Myovant Sciences Gmb...

ID:NCT03751124

SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain

Phase 3

Completed

Posted: 2018/08/31

Sponsor:Myovant Sciences Gmb...

ID:NCT03654274

Effects of Restrictive Fluid Strategy on Postoperative Oliguric Pancreatic Surgery Patients

Not Applicable

Terminated

Posted: 2018/06/12

Sponsor:

Uppsala University

ID:NCT03553394

LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Phase 3

Completed

Posted: 2018/01/29

Sponsor:Myovant Sciences Gmb...

ID:NCT03412890

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Pfizer to Showcase Breakthrough Cancer Therapies at ASCO 2025 with Over 60 Presentations

a month ago

Pfizer will present data from more than 60 abstracts at ASCO 2025, including 15 oral presentations highlighting advancements across breast, genitourinary, hematologic, thoracic, and colorectal cancers.

Pathos AI Initiates Phase 1b/2a Trial of Pocenbrodib for Metastatic Castration-Resistant Prostate Cancer

2 months ago

Pathos AI has dosed the first patient in a Phase 1b/2a trial evaluating pocenbrodib, a CBP/p300 inhibitor, alone and in combination with established therapies for metastatic castration-resistant prostate cancer.

TALAPRO-2 Trial: Talazoparib-Enzalutamide Combo Shows Significant Survival Benefit in Metastatic Prostate Cancer

3 months ago

The combination of talazoparib and enzalutamide demonstrated an 8.8-month improvement in overall survival compared to enzalutamide alone in metastatic castration-resistant prostate cancer patients.

Verastem's Avutometinib and Defactinib Combination Receives FDA Priority Review for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

5 months ago

The FDA has granted Priority Review to Verastem Oncology's NDA for avutometinib combined with defactinib for recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC).

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy